Court upholds Bausch Health victory in Xifaxan fight; Norwich generic blocked until 2029

A U.S. District Court judge in Delaware has denied Norwich Pharmaceuticals’ motion to modify the court’s final judgment, which blocks the FDA from approving their 550 mg rifaximin generic until Oct. 2, 2029.This decision by Judge Richard G. Andrews bolsters his previous ruling that Norwich’s abbreviated new drug application for rifaximin infringed on Bausch Health’s Xifaxan (rifaximin) patents for the reduction in risk of hepatic encephalopathy (HE) recurrence.In his final judgement, Andrews “ordered the FDA not to approve the ANDA before the latest expirationRead More